This live session took place on Wednesday, May 3rd 2017.

Dr. Johnson Olabisi, MBBS., M.Sc., Associate Epidemiologist, will present DRG’s epidemiological forecast of all those living with gastroesophageal cancer worldwide in 2017 and 2027. The numbers will be presented by world region and country income status, as well as by stage and drug treatability status.

During this presentation, you will learn:

  • How many people worldwide are living with diagnosed gastroesophageal cancer (classified by major histology types) and how will this number change over the coming decade, and what factors will be driving the change?
  • Which world regions have the greatest number of people living with gastroesophageal cancer (classified by major histology types), and which will show the greatest growth in cases over the coming decade?
  • Of all those living with gastroesophageal cancer worldwide, what proportion have metastatic vs non-metastatic disease?
  • How would the stage distribution of gastroesophageal cancer change in low income countries based on projected growth in the country’s GDP per capita?
  • How many people living with gastroesophageal cancer are drug treatable?

Presented by Dr. Johnson Olabisi, MBBS., M.Sc., Associate Epidemiologist

What drives the therapy selection test market?

View Now